There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Results showed patients with a BMI of 40 kg/m2 or more who used glucagon-like peptide-1 receptor agonists for at least 90 ...

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...